跳至主要内容
临床试验/ACTRN12621000635864
ACTRN12621000635864招募中未知

Takotsubo cardiomyopathy: Truly a syndrome of cardiac catecholamine excess? Understanding the effects on cardiac sympathetic nerve activity.

Prof Markus Schlaich0 个研究点目标入组 80 人开始时间: 2021年5月27日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients presenting with symptoms indicative of Takotsubo Syndrome per diagnostic criteria, including acute cardiac chest pain and/or shortness of breath will have routine investigations including ECG, high sensitivity troponin levels, BNP/NT pro-BNP and trans thoracic echocardiogram. Those who fulfil the inclusion criteria of (1) typical clinical symptoms, (2) relevant electrographic changes and cardiac biomarker profile consistent with Takotsubo Syndrome and (3) relevant echocardiographic characteristics, will be enrolled in the study. Diagnosis criteria is per HF Association diagnostic criteria and includes:
  • (1) transient regional wall motion abnormalities of LV or right ventricle myocardium which are frequently but not always preceded by a stressful trigger;
  • (2) the regional wall motion abnormalities usually extend beyond a single epicardial vascular distribution and often results in circumferential dysfunction of the ventricular segment
  • (3) the absence of culprit atherosclerotic CAD including acute plaque rupture, thrombus
  • formation and coronary dissection or other pathological conditions to explain the pattern of temporary LV dysfunction observed (e.g. hypertrophic cardiomyopathy, viral myocarditis);
  • (4) new and reversible electrocardiography (ECG) abnormalities (ST-segment elevation, ST-depression, LBBB, T-wave inversion and/or QTc prolongation) during the acute phase (less than 3 months);
  • (5) significantly elevated BNP or NT-proBNP during the acute phase;
  • (6) positive but relatively small elevation in cardiac troponin measured with a conventional assay (i.e. troponin negative levels is possible);
  • (7) recovery of ventricular systolic dysfunction on cardiac imaging at follow-up (after 3 months).

排除标准

  • In ~25% of patients, significant coronary artery disease will be detected and account for their symptoms. If a coronary artery stenosis is detected during coronary angiography, percutaneous coronary interventions if required, will be performed as deemed appropriate by
  • the treating physician and management and follow up arranged as per standard guidelines. If deemed safe by the interventional cardiologist, these patients may still undergo cardiac NA/A spillover assessment and will serve as a control group” for those with Takotsubo Syndrome. If not, they will be excluded from the study.

研究者

发起方
Prof Markus Schlaich

相似试验